BioLineRx Ltd (BLRX) - Financial and Strategic SWOT Analysis Review

BioLineRx Ltd (BLRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.


The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

BioLineRx Ltd (BioLineRx) is a clinical-stage biopharmaceutical company that focuses on the development of products related to cancer and immunology. Its pipeline product BL-8040 is for the treatment of acute myeloid leukemia (AML) and relapsed or refractory AML. The company’s other pipeline drug candidate AGI-134 is synthetic alpha-gal immunotherapy that finds application in the treatment of solid tumors. BioLineRx's only product BL-5010 is a novel medical device indicated for the non-surgical removal of skin lesions. BioLineRx is headquartered in Modi'in-Maccabim-Re'ut, Israel.

BioLineRx Ltd Key Recent Developments

May 24,2023: BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
May 17,2023: BioLineRx to report Q1 2023 results on May 24, 2023
Mar 22,2023: BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates
Jan 04,2023: BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
BioLineRx Ltd - Key Facts
BioLineRx Ltd - Key Employees
BioLineRx Ltd - Key Employee Biographies
BioLineRx Ltd - Major Products and Services
BioLineRx Ltd - History
BioLineRx Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
BioLineRx Ltd - Business Description
R&D Overview
BioLineRx Ltd - Corporate Strategy
BioLineRx Ltd - SWOT Analysis
SWOT Analysis - Overview
BioLineRx Ltd - Strengths
BioLineRx Ltd - Weaknesses
BioLineRx Ltd - Opportunities
BioLineRx Ltd - Threats
BioLineRx Ltd - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
BioLineRx Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 24, 2023: BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
May 17, 2023: BioLineRx to report Q1 2023 results on May 24, 2023
Mar 22, 2023: BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates
Jan 04, 2023: BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer
Nov 15, 2022: BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updates
Aug 16, 2022: BioLineRx Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Jun 16, 2022: BioLineRx Announces Appointment of Commercial Strategy and Operations Veteran Holly W. May as Chief Commercial Officer
May 11, 2022: BioLineRx Reports First Quarter 2022 Financial Results and Provides Corporate Update
Mar 16, 2022: BioLineRx Reports Year-End 2021 Financial Results and Provides Corporate Update
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
BioLineRx Ltd, Key Facts
BioLineRx Ltd, Key Employees
BioLineRx Ltd, Key Employee Biographies
BioLineRx Ltd, Major Products and Services
BioLineRx Ltd, History
BioLineRx Ltd, Subsidiaries
BioLineRx Ltd, Key Competitors
BioLineRx Ltd, Ratios based on current share price
BioLineRx Ltd, Annual Ratios
BioLineRx Ltd, Annual Ratios (Cont...1)
BioLineRx Ltd, Interim Ratios
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
BioLineRx Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
BioLineRx Ltd, Performance Chart (2018 - 2022)
BioLineRx Ltd, Ratio Charts
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings